Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Background Atopic dermatitis (AD) is an inflammatory skin condition with multiple systemic
treatments and uncertainty regarding their comparative impact on AD outcomes. Objective …

Importance Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-
13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis …

Background For people with atopic dermatitis (AD) refractory to topical therapies, treatment
with phototherapy and systemic therapies can be considered. Multiple biologic therapies …

Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for
the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab …

Therapeutic options for people with moderate or severe atopic dermatitis refractory to topical
therapy have rapidly expanded in recent years. These new targeted immunomodulatory …

Importance There are multiple approved systemic treatments for atopic dermatitis.
Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in …

Health technology assessments (HTAs) are typically performed as one-off evaluations and
can potentially become out-of-date due to the availability of new data, new comparators, or …

Introduction The efficacy and safety of upadacitinib in atopic dermatitis have been defined in
clinical trials, but long-term real-life experience, essential for clinical decision-making, is still …

The US Food and Drug Administration approval of dupilumab for moderate-to-severe atopic
dermatitis shifted the paradigm from use of broad, systemic immunosuppressants to a safer …